International Vaccine Institute strategic demand forecasting; and Sabin – communications and advocacy. Besides leading the consortium, IVI generated evidence for decision-making such as disease burden, country vaccine introduction cases and a global investment case. From 2010 to 2016, DVI operated in Brazil, Burkina Faso, Cambodia, Colombia, Gabon, India, Kenya, Thailand, and Vietnam. From 2013-2015, with funding from Germany’s Federal Ministry of Education & Research (BMBF), IVI continued support for preclinical development of dengue vaccines by Brazil’s Butantan Institute and Vietnam’s VaBiotech. After the 2016 licensure of Sanofi Pasteur’s Dengvaxia vaccine, the DVI project came to a close and its IVI staff transitioned to
The Reform Institute to overcome the challenges we collectively face and emerge as a stronger country. A resilient nation requires: a fully transparent and accountable government, a citizenry that is actively engaged in the political process and has genuine access to the wealth of opportunities that the free market has to offer, and institutions and infrastructure capable of facilitating and taking full advantage of the ingenuity and determination of the American people by promoting private sector innovation." The Institute was criticized during the 2000 decade as an extension of Senator John McCain's political ambitions. The New York Times described the Institute in this